Test Price
2,800 AED✅ Home Collection Available
SLC16A1 Gene Hyperinsulinemic Hypoglycemia Type 7 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This NGS‑based genetic test provides 99.9% diagnostic sensitivity for SLC16A1‑related hyperinsulinemic hypoglycemia, fully compliant with DHA regulations and ISO 9001:2015 standards.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic post‑test counseling with a DHA‑licensed genetics expert for result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731 (English & Arabic support).
Test Overview & Methodology
The SLC16A1 gene test definitively identifies pathogenic variants responsible for familial hyperinsulinemic hypoglycemia type 7. Using Next‑Generation Sequencing (NGS), the entire coding region and splice sites are analysed, enabling precise diagnosis and personalised management. The test detects all mutation types—missense, nonsense, frameshift, and splice‑site alterations—with a sensitivity exceeding 99.9%.
| Parameter | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity; detection of all mutation types | ~95%, limited to known hotspots |
| Molecular Method | Next‑Generation Sequencing (full gene coverage) | Sanger sequencing of exons & splice sites |
| Turnaround Time | 3–4 weeks (definitive report) | 4–6 weeks, often with resolution testing |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I understand the emotional burden of investigating familial hypoglycemia. The SLC16A1 analysis delivers definitive molecular answers, but every result must be correlated clinically with the patient’s metabolic profile and family history. Never adjust treatment without consulting your physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Important: Do not discontinue or change any prescribed medication, including diazoxide or glucagon, without explicit guidance from your treating endocrinologist. Genetic test results do not replace clinical judgment.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Acute illness with fever, recent blood transfusion (within 8 weeks), or inability to provide informed consent. For paediatric patients, guardian consent must follow DHA regulations.
- Exclusion: Concurrent use of medications known to interfere with NGS library preparation—please inform our phlebotomist of all current treatments.
- ER Red Flag: If the patient experiences severe hypoglycemic symptoms (confusion, seizure, loss of consciousness), call 998 immediately and proceed to the nearest emergency department.
- ER Red Flag: Sudden onset of diaphoresis, tachycardia, or neuroglycopenic symptoms while fasting—urgent medical evaluation is required.
Patient FAQ & Clinical Guidance
1. What is the SLC16A1 gene test for hyperinsulinemic hypoglycemia?
The test detects pathogenic variants in the SLC16A1 gene that cause congenital hyperinsulinemic hypoglycemia type 7. Using NGS, the entire coding region is analysed to identify mutations leading to excessive insulin secretion. A positive result confirms the molecular diagnosis and guides family screening and treatment decisions such as dietary modifications or pharmacotherapy with diazoxide.
2. How is the test performed and what sample is needed?
A simple blood sample or dried blood spot on an FTA card is collected at your home by our trained phlebotomist under cold‑chain protocols. The sample is transported to our ISO‑certified laboratory, where the SLC16A1 gene is fully sequenced. Results are interpreted by board‑certified geneticists. The procedure is minimally invasive and suitable for paediatric patients.
3. What is the cost and turnaround time in the UAE?
The test costs 2,800 AED, with results available within 3–4 weeks. The fee includes genetic counseling, home collection, laboratory analysis, and a detailed clinical report. Insurance pre‑authorisation can be verified via WhatsApp within minutes. The test complies with UAE data protection laws, ensuring your personal health information remains confidential.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA) and complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your genetic data is handled with the highest encryption and access controls.
Clinical & Logistical Metadata
| Test Name | SLC16A1 Gene Hyperinsulinemic Hypoglycemia Type 7 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) or dried blood spot on FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coverage |
| ICD‑10‑CM Code | E16.1 |
| LOINC Code | 82619-4 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians